Apr 1 |
Bristol Myers' (BMY) Zeposia Fails Crohn's Disease Study
|
Apr 1 |
Investors in ADMA Biologics (NASDAQ:ADMA) have seen splendid returns of 261% over the past three years
|
Mar 28 |
Moderna (MRNA) Posts Pipeline Progress, Secures Blackstone Funding
|
Mar 27 |
Praxis (PRAX) Surges on Positive Epilepsy Study Results
|
Mar 27 |
Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair
|
Mar 26 |
Axsome's (AXSM) Narcolepsy Drug Study Meets Primary Goal
|
Mar 26 |
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication
|
Mar 26 |
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
|
Mar 22 |
Why the Market Dipped But Adma Biologics (ADMA) Gained Today
|
Mar 22 |
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
|